Pharmaceutical_side | Wall Street Endeavor

top of page

WSE_logo_artwork-rgb_outline_dark green.png

Ultragenyx’s $203 Million Voucher Deal Offers a Funding Boost

Ultragenyx’s $203 Million Voucher Deal Offers a Funding Boost

Ultragenyx’s $203 Million Voucher Deal Offers a Funding Boost

6 days ago1 min read

Syndax Trial Failure Narrows Its Growth Outlook

Syndax Trial Failure Narrows Its Growth Outlook

Syndax Trial Failure Narrows Its Growth Outlook

Oct 131 min read

Merck’s Keytruda Expansion Hits a European Roadblock

Merck’s Keytruda Expansion Hits a European Roadblock

Merck’s Keytruda Expansion Hits a European Roadblock

Oct 131 min read

Nvidia-Backed Drug Developer Targets $159 Million IPO

Nvidia-Backed Drug Developer Targets $159 Million IPO

Nvidia-Backed Drug Developer Targets $159 Million IPO

Oct 131 min read

Genmab Rises as AbbVie Cancer Trial Opens Growth Opportunity

Genmab Rises as AbbVie Cancer Trial Opens Growth Opportunity

Genmab Rises as AbbVie Cancer Trial Opens Growth Opportunity

Oct 71 min read

Worthy Endeavor Spotlight: Quantum BioPharma Ltd. (NASDAQ: QNTM)

Worthy Endeavor Spotlight: Quantum BioPharma Ltd. (NASDAQ: QNTM)

Worthy Endeavor Spotlight: Quantum BioPharma Ltd. (NASDAQ: QNTM)

Worthy Endeavors

Oct 71 min read

AstraZeneca Seeks US Approval for Lung Cancer Drug Combination

AstraZeneca Seeks US Approval for Lung Cancer Drug Combination

AstraZeneca Seeks US Approval for Lung Cancer Drug Combination

Oct 11 min read

Roche Wins New US Approval for Gazyva

Roche Wins New US Approval for Gazyva

Roche Wins New US Approval for Gazyva

Oct 11 min read

ADARx Raises $446 Million as Biotech IPOs Regain Momentum

ADARx Raises $446 Million as Biotech IPOs Regain Momentum

ADARx Raises $446 Million as Biotech IPOs Regain Momentum

Sep 281 min read

Genentech Makes a $1.5 Billion Bet on AI-Designed Cancer Drugs

Genentech Makes a $1.5 Billion Bet on AI-Designed Cancer Drugs

Genentech Makes a $1.5 Billion Bet on AI-Designed Cancer Drugs

Sep 281 min read

Viking’s Weight-Loss Drug Has a New Selling Point: Fewer Injections

Viking’s Weight-Loss Drug Has a New Selling Point: Fewer Injections

Viking’s Weight-Loss Drug Has a New Selling Point: Fewer Injections

Sep 242 min read

Grail’s Cancer Test Faces Its Most Important Question Yet

Grail’s Cancer Test Faces Its Most Important Question Yet

Grail’s Cancer Test Faces Its Most Important Question Yet

Sep 241 min read

MapLight’s Schizophrenia Drug Worked, but Can It Compete?

MapLight’s Schizophrenia Drug Worked, but Can It Compete?

MapLight’s Schizophrenia Drug Worked, but Can It Compete?

Sep 162 min read

Merck Isn't Reinventing Cholesterol Drugs It's Reinventing How Patients Use Them

Merck Isn't Reinventing Cholesterol Drugs It's Reinventing How Patients Use Them

Merck Isn't Reinventing Cholesterol Drugs It's Reinventing How Patients Use Them

Sep 142 min read

Trump’s Drug Pricing Push Could Put Smaller Pharma Firms Under Pressure

Trump’s Drug Pricing Push Could Put Smaller Pharma Firms Under Pressure

Trump’s Drug Pricing Push Could Put Smaller Pharma Firms Under Pressure

Aug 101 min read

2

bottom of page